



New York office:
1460 Broadway
New York
NY 10036, USA
Tel: +1-929-274-7510

London office:
75-76 Wimpole Street
London W1G 9RT, UK
Tel: +44 (0) 20 8 0040261

To Whom It May Concern:

Akari is committed to the disclosure of results for interventional clinical trials conducted in the EEC per the requirements of Commission Guideline 2012/C 302/03. The trial listed below was registered with the EudraCT database but was cancelled/ withdrawn before it started and never enrolled any participants.

Please note that on 17-APR-2019 this trial was prematurely ended due to the lack of eligible patients for this clinical trial. No patients were enrolled to the study. Therefore, early termination will result in the inability to perform analysis of endpoints outlined in the protocol. A risk-benefit assessment can also not be performed for this reasoning.

No patient data or results will be generated from the AK601 study.

EudraCT# 2017-000064-15

Study Title: A Phase 2, single arm study of Safety and Efficacy of Coversin in adult aHUS subjects

Sponsor Name: Akari Therapeutics Plc